A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer
about
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized DosingStromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
P2860
A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase II study of GW786034 ( ...... tion-resistant prostate cancer
@ast
A phase II study of GW786034 ( ...... tion-resistant prostate cancer
@en
A phase II study of GW786034
@nl
type
label
A phase II study of GW786034 ( ...... tion-resistant prostate cancer
@ast
A phase II study of GW786034 ( ...... tion-resistant prostate cancer
@en
A phase II study of GW786034
@nl
prefLabel
A phase II study of GW786034 ( ...... tion-resistant prostate cancer
@ast
A phase II study of GW786034 ( ...... tion-resistant prostate cancer
@en
A phase II study of GW786034
@nl
P2093
P2860
P1476
A phase II study of GW786034 ( ...... tion-resistant prostate cancer
@en
P2093
Christopher M Booth
Jovana Golubovic
Nevin Murray
Pamela Harris
Richard Gregg
Srikala S Sridhar
P2860
P304
P356
10.1016/J.CLGC.2014.06.001
P407
P577
2014-06-08T00:00:00Z